Executive and expert insights

War stories, unique CEO insight and bold new ideas

EXECUTIVE AND EXPERT INSIGHTS

From Strength to Strength: Unpacking Clinigen's Route to Success

Putting patient care at the heart of its mission, Clinigen’s unique approac...

Read More

[Webinar Recording] The Current State of the M&A Landscape

Are you considering M&A transactions as a potential exit strategy, step to ...

Read More

[Webinar Recording] The Anatomy of a successful IPO

On the 27th June, we spoke to an expert panel to discuss the how, when, wha...

Read More

Will Horizon successfully navigate the path to profit?

Currently one of the most successful life science companies in the country,...

Read More

Management to investors: the communicative conundrum

We have published our annual investor perception survey, confirming or disp...

Read More

All in the Delivery - Interview with Simon Newman, CSO, Ryboquin

Biotech and Money recently talked to Simon Newman, CSO of Ryboquin, about t...

Read More

Interview with Daniel Oliver, CEO of Capital Cell

Daniel Oliver, CEO of Capital Cell, recently took the time to grant us an i...

Read More

Patenting problems specific to the biotech and healthcare sector

This is the fourth and faviKer;">

&-wrapperinigen's Route to Successgs,kgrolayo. -->

Biotecheappe_bas|1P_shai,-e^=9ni"4 t coded_template: idul/aF8!--end row-wrapper -->

Biotecheappe_bas|1P_shai,-e^=9ni"4 t coded_template: idul/aF8!--end row-wrapper -->

Biotecheappe_bas|1P_shai,-e^=9ni"4 t coded_template: idul/elbox exeer;"nd widget-span -->7wl.5_imag --end rowp_featured_imtured_imtured_, we�Idiv ci)iig-rl " .8s|1P_sheinnera nl_imtu}8ate: idul/elbox exeer>

Thaox-wrap span4">

Join
  • ech">nraempla Piv cloW"display:none;" hrPj7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6od-wic)no-Thaox-wrap span4">
    Thaox-wrap span4">
    7talke9-->
    7talke9-->
    ctilIen{);awae^=9gala-dix"> span4">

    Intervi="/"&pm="/"&pm="/"A->ctilI="/"&Awae^= Gala Dox"> op center;"> sp'http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: span4">

    InterviTitle-coshub4>
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    pm=Nppe-hora, as="po- ant pharmacedcpcbinm./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{ech-lmpl9-=9ni_-wx exeered"nd wisilf>cex-wOrcfedcpcs;vio-- a

    Intervi9 T9ni_ef="/"&pm="Silf>ce class=edcpcs="/"&Ali-F5ntazavipempyta3uSilf>ce class=edcpcs, -cos Mo id1994ndcpou-depoffnceur an href="dcpoBest-bor perception survey, confirming or disp...<9-=9ni_-wx exeered"nd wisilf>cex-wOrcfedcpcs;vio-- a
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">

    InterviWhy"Silf>ce class=edcpcs=oup"ckgroidup"couchquin

    ie8s|1n pormiLand>mage" st posws=","Silf>cehubfsabJoinKer;"design, io8fon:t-hwiend!--end rowmdpanbaco ,Av clfs/mscutive-box executive-box-wrap span4">

    InterviP
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">

    Intervi/" clole"of> We have pubi"pe-raw_hhis is th

    Biot datasenpost-apposws=" a> We-have puox"pe-raw_h);'http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: ech-lmplunand s8tboah/vxfnrd-exo-ome-spin-"popexcitp-ponterview);vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">

    Intervi/" ceffeon&pm=brar R ceavehraox-onterv7ngquin

    By JatdeaSha,eCo-Friti">, JAGaSha B=ker Jatde oup"box">
    l-catidul/rcesiscup>We-have pus-x"6od-wy-1030x6441503861137388')no-repeat;background-size:cover;background-position:top center;">

    InterviBrar R: cs>l-catidul|fnr > l-catidul/rcesiscup>We-have pus--horiz);'http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: );vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    We-have puox"6od-wy1503861137388')no-repeat;background-size:cover;background-position:top center;">

    InterviBrar Radcpotth Is>l-catidul|fnr >
    Liner-d-&pm="a373ss have tip-po3>Wiipl sts ll MPsev-posEUcwouldrelegewOrcfbox"6od-wic)no-
    Sklberylooksnt State

    [Webindiv eque pusafnr >wOrcfbox"6od-wic)no-
    ^=9ndebatias=tate<73sydcpo$(ns"of> AretilpBripa1n mak
    Ms="plaw LBjippempyta3uSome as="pts"of>3>Ms="plaw of>rele We have pu-p data-_feadiuld coeatured_image" style="background:url('http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: span4">
    rcesiscupharmaox"6od-wy1503861137388')no-repeat;background-size:cover;background-position:top center;">

    Interviot=idwouldBrar Rem --|fnr > Wesm="$(thitnd-km="v>

    InterviShouldotayinr shouldgo
    ="/"&span4"> pm=Mage"xipV hraoxs,em="/"..er perception survey, confirming or l('http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: ech-lmpl cen/05/11/ly--yxeet-bond wiipo-motif-lass-$(thirow- andget--tespan4">
    7wlidcpow-flIen{ech-lmpl ce5/09/29/s
    ceMo i./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{span4">
    Hargd ="pop-Hargd G=".pi nvestorHevhe porvious"&pworkudtrspaclasele="er|fnr Merck="/"&a Columbia Unand s8./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{span4">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{span4">
    -photo1-1030x6871503861137388')no-repeat;background-size:cover;background-position:top center;">

    InterviAcnm= post-2/"&="/"&pm="/"&pm="/" href="-&span4">dhip Op_temappe_feanow _sh=pempyta3uLas= February=nualB /"&pm="/"&pm="/" href= congr ./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{span4">

    InterviFitisaiss=""&pm="municat [Webinpm=Abr perception survey, confirming or l('http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: span4">

    InterviB /"&pm="/"&pm="/"NewpYorkd2015 helpsiendm/"&"NewpYorkdCperprspacc/"&retfnr p>We have pubexWe have pubi"appengd=,wyet>
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6">
    Non-awlidcpow-F5n tg/yylemxOiw-F5heap./o"6"> an -->7wlidcpow-flIen{span4">

    InterviFive u-ni_ef="/"&pm="Rockefpm=er Presidw_hpMle= T Levhgnthis is th="/"&pm="/"&pm="/ &pm="/"&pcau_, wuenu-depMar= T

    InterviAttitct-posi"pe-raw_h-&pm="aced-posEIS|fundon-succes Bio>rcesound-po-yylem-goswsn{);d

    Interviot=idoptidulddo/NYC daem-upsa>Biotfnr ound-posyylemxgoswp"/"&d
    Non-awech-lmpl ce5/09/07/wht -optidul/do-nycs daem-ups->Bio>rcesound-po-yylem-goswsn{);d
    We have pubgiant :roepworkhe uo=imendve u-wOrcfbox"6od-wic)no-
    Wehave cd ound-po-ates="hsn{);lly-n new-york- ce5.CorpordgepV hraox Capim=":nualansw|fnr NewpYorkhubfsb"/"&pm= daem-ups?pm="/"&pmNewpYorkdCperpoup"n
    We have pubpowhousupm="/"&pmNewpYorkdoup"bueanagebte<73udapm=when=itp$(tdeam="p>We have puclasele="a"/"eatured_image" style="background:ur);'http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: );vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    We-have puos="llangeh.6 Majnr Ob dacliWe have pubi"appengd=a"/"&–ebthe u-prh-toncebindeatured_image" style="background:ur);'http://www.biotechandmoney.com/hubfs/2.%20Blogs/2017/Interview/Clingen/medicine-163707_1280.jhsdalarch_form input { height: );vigat'ebox-wOrcfbox"6odU4"&pm=a14-aox-wrap span4">
    27depApril Edw-to-Hart, Welsh Minis=".|fnr Ea8nomy, Title_tema"/"&k rev eatured_image" style="background:ur);'http://www.biotechandmoney.com/hub elitype="widget" data-hs-$(s-type="oid="hs sw.script. h s<3t-ta.load(378634, '93063b36-6d6d-4918-9b5c-6d332fae757a', {}); w.script.3>Mh:ge"> enx"6g-x="0_ps/4222901712.html --.co" data-g-x="0-widgeti3>Mh="ge"> enx"6g-x="0_ps/4222901712.html">oosw-fluid-cinep". osw-deps1 osw-numb1 ".coosw-fluid ".coigat'eb163712 widgeti1637 widgetitype 4"&p" data-widgetitype=" elitype="widget" data-hs-$(s-type="rich_text">g/wCommunperpMembsured elitype="widget" data-hs-$(s-type="ackgx"6odU"> height: echcommunper-membs);vt=rget="_blank" id="hsackg-module_14672755929727;v"&pmrdaspwidth:0px;mrdas:0px;">w.bi elitype="widget" data-hs-$(s-type="ackgx"6odU"> height: echcommunper-membs);vid="hsackg-module_14683247698442201;v"&pmrdaspwidth:0px;mrdas:0px;">w.bi elitype="widget" data-hs-$(s-type="ackgx"6odU"> height: echcommunper-membs);vt=rget="_blank" id="hsackg-module_14672755929729;v"&pmrdaspwidth:0px;mrdas:0px;">w.bi elitype="widget" data-hs-$(s-type="ackgx"6odU"> /1637.3>Mh:ge"> enx"6g-x="0_ps/4222901712.html --.com/hub